CNO Stock Analysis: CNO Financial | NYSE
Insurance - Life | NYSE, USA | Market Cap: 5.113m USD | 12M Return: 50% | US12621E1038 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 35.4M
EPS Trend: 86.5%
Qual. Beats: 1
Rev. Trend: 82.6%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CNO Financial Group, Inc. is a U.S.-based insurance holding company that develops, markets, and administers health insurance, annuity, individual life insurance, and related financial products aimed at middle-income pre-retiree and retired Americans. Operating through its subsidiaries, the company distributes Medicare supplement, supplemental health, long-term care insurance, Medicare advantage plans, life insurance, and annuities through phone, online, virtual, and face-to-face channels with agents, as well as through workplace-based sales of voluntary benefit products.
The companys product portfolio spans fixed indexed annuities, fixed interest and flexible premium deferred annuities, single premium immediate annuities, supplemental health products (including specified disease, accident, and hospital indemnity coverage), long-term care plans, universal life and other interest-sensitive life products, and traditional life policies such as whole life, graded benefit life, term life, and single premium whole life. Its offerings are marketed under three primary brand names: Bankers Life, Washington National, and Colonial Penn, each serving different customer segments within the middle-income market.
CNO Financial Group was founded in 1979 and is headquartered in Carmel, Indiana. The company has traded on the NYSE since 1987 and is classified within the Financials sector under the Life & Health Insurance sub-industry. Its focus on the middle-income pre-retiree and retired demographic represents a specialized niche within the broader U.S. insurance industry, leveraging a multi-brand, multi-channel distribution strategy tailored to that customer base.
- Fed rate cuts pressure fixed annuity investment margins
- Medicare supplement enrollment growth boosts premium revenue
- Long-term care reserve charges pressure reported earnings
| Net Income: 279.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.90 > 1.0 |
| NWC/Revenue: -385.6% < 20% (prev -101.1%; Δ -284.4% < -1%) |
| CFO/TA 0.02 > 3% & CFO 698.9m > Net Income 279.6m |
| Net Debt (3.25b) to EBITDA (733.6m): 4.43 < 3 |
| Current Ratio: 0.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (95.0m) vs 12m ago -7.88% < -2% |
| Gross Margin: 43.42% > 18% (prev 38.31%; Δ 5.12% > 0.5%) |
| Asset Turnover: 12.05% > 50% (prev 11.74%; Δ 0.31% > 0%) |
| Interest Coverage Ratio: 2.65 > 6 (EBIT TTM 571.7m / Interest Expense TTM 216.0m) |
| A: -0.45 (Total Current Assets 1.31b - Total Current Liabilities 19.2b) / Total Assets 39.8b |
| B: 0.06 (Retained Earnings 2.55b / Total Assets 39.8b) |
| C: 0.01 (EBIT TTM 571.7m / Avg Total Assets 38.6b) |
| D: 0.07 (Book Value of Equity 2.59b / Total Liabilities 37.2b) |
| Altman-Z'' = -2.57 = D |
As of August 12, 2026, the stock is trading at USD 54.63 with a total of 419,237 shares traded. Over the past week, the price has changed by -1.41%, over one month by +4.66%, over three months by +20.04% and over the past year by +49.97%.
Current recommended Stop Loss: 52.30 (which is 4.3% or 2.1 ATR below the current price).
CNO Financial has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CNO.
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 53.5 | -2.1% |
P/E Trailing = 19.0207
P/E Forward = 9.7847
P/S = 1.1004
P/B = 1.9819
P/EG = 1.287
Revenue TTM = 4.65b USD
EBIT TTM = 571.7m USD
EBITDA TTM = 733.6m USD
Long Term Debt = 4.05b USD (from longTermDebt, last fiscal year)
Short Term Debt = unknown (none)
Debt = 4.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.25b USD (calculated: Debt 4.55b - CCE 1.31b)
Enterprise Value = 8.36b USD (5.11b + Debt 4.55b - CCE 1.31b)
Interest Coverage Ratio = 2.65 (Ebit TTM 571.7m / Interest Expense TTM 216.0m)
EV/FCF = 30.08x (Enterprise Value 8.36b / FCF TTM 277.9m)
FCF Yield = 3.32% (FCF TTM 277.9m / Enterprise Value 8.36b)
FCF Margin = 5.98% (FCF TTM 277.9m / Revenue TTM 4.65b)
Net Margin = 6.02% (Net Income TTM 279.6m / Revenue TTM 4.65b)
Gross Margin = 43.42% ((Revenue TTM 4.65b - Cost of Revenue TTM 2.63b) / Revenue TTM)
Gross Margin QoQ = 43.42% (prev 44.63%)
Tobins Q-Ratio = 0.21 (Enterprise Value 8.36b / Total Assets 39.8b)
Interest Expense / Debt = 4.74% (Interest Expense 216.0m / Debt 4.55b)
Taxrate = 21.39% (76.1m / 355.7m)
NOPAT = 449.4m (EBIT 571.7m * (1 - 21.39%))
Current Ratio = 0.07 (Total Current Assets 1.31b / Total Current Liabilities 19.3b)
Debt / Equity = 1.76 (Debt 4.55b / totalStockholderEquity, last quarter 2.59b)
Debt / EBITDA = 4.43 (Net Debt 3.25b / EBITDA 733.6m)
Debt / FCF = 11.68 (Net Debt 3.25b / FCF TTM 277.9m)
Total Stockholder Equity = 2.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.73% (Net Income 279.6m / Total Assets 39.8b)
RoE = 10.82% (Net Income TTM 279.6m / Total Stockholder Equity 2.58b)
RoCE = 8.61% (EBIT 571.7m / Capital Employed (Equity 2.58b + L.T.Debt 4.05b))
RoIC = 1.14% (NOPAT 449.4m / Invested Capital 39.5b)
WACC = 5.99% (E(5.11b)/V(9.67b) * Re(8.0%) + D(4.55b)/V(9.67b) * Rd(4.74%) * (1-Tc(0.21)))
Discount Rate = 8.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.93 | Cagr: -6.65%
[DCF] Terminal Value 73.10% ; FCFF base≈405.1m ; Y1≈355.2m ; Y5≈287.0m
[DCF] Fair Price = 14.67 (EV 4.61b - Net Debt 3.25b = Equity 1.36b / Shares 92.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 86.53 | EPS CAGR: 18.39% | SUE: 0.90 | # QB: 1
Revenue Correlation: 82.63 | Revenue CAGR: 4.07% | SUE: 1.17 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.06 | Chg30d=-2.30% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=4.48 | Chg30d=-0.04% | Revisions=-25% | GrowthEPS=+1.8% | GrowthRev=-9.7%
EPS next Year (2027-12-31): EPS=4.95 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+10.6% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: -50% (up=0, down=3)